Global Infantile Spasms Therapeutics Market to Reach US$ 5.1 Billion by 2032, Facilitated by Increasing Incidences of Infantile Spasms

July 12, 2023 | Healthcare

According to the latest report by IMARC Group, titled “Infantile Spasms Therapeutics Market by Therapeutic Class (Anticonvulsants, Corticosteroids, and Others), Drug Type (Vigabatrin, Adrenocorticotropic Hormone, and Others (Phase III)), Dosage (Solid, Liquid), Route of Administration (Oral, Parenteral, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), End User (Hospitals, Clinics, and Others), and Region 2024-2032,” the global infantile spasms therapeutics market size reached US$ 3.6 Billion in 2023. Infantile spasms, also known as West syndrome, refers to a rare and severe form of epilepsy that typically affects infants between the ages of 3 and 12 months. They are characterized by brief symmetric muscle contractions that can cause the body or limbs to jerk or flex. They can be diagnosed by physical examination, neurological examination, magnetic resonance imaging (MRI) of the brain, and blood and urine examinations. They involve a combination of medication and therapies, such as steroids, hormone therapy with corticotropin injection gel and glucocorticoids, and antiseizure medications.

Global Infantile Spasms Therapeutics Market Trends:

The increasing incidences of infantile spasms among infants represent one of the major factors driving the demand for infantile spasms therapeutics around the world. Moreover, the rising awareness about the early signs and symptoms of infantile spasms and improved diagnostics capabilities is favoring the growth of the market. In addition, governing agencies of several countries are offering financial assistance for infantile spasms treatment to minimize healthcare expenses. Apart from this, they are financing research and development (R&D) projects to identify and develop novel therapeutic agents. This, coupled with the increasing number of clinical trials by pharmaceutical companies, is augmenting the growth of the market. Looking forward, the market value is projected to reach US$ 5.1 Billion by 2032, expanding at a CAGR of 3.7% during 2024-2032.

Market Summary:

  • Based on the therapeutic class, the market has been segmented into anticonvulsants, corticosteroids, and others. Anticonvulsants currently account for the majority of the total market share.
  • On the basis of the drug type, the market has been segregated into vigabatrin, adrenocorticotropic hormone, and others (phase III). Adrenocorticotropic hormone holds the biggest share in the market.
  • Based on the dosage, liquid dominates the market, followed by solid.
  • On the basis of the route of administration, the market has been divided into oral, parenteral, and others. Presently, parenteral exhibits a clear dominance in the market.
  • Based on the distribution channel, the market has been classified into hospital pharmacy, retail pharmacy, and online pharmacy. At present, hospital pharmacy dominates the market.
  • On the basis of the end user, the market has been categorized into hospitals, clinics, and others. Presently, hospitals account for the majority of the market share.
  • Region-wise, the market has been segmented into North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. Amongst these, North America enjoys the leading position in the market.
  • The competitive landscape of the market has also been examined, with some of the key players being H. Lundbeck A/S, Mallinckrodt plc, ORPHELIA Pharma, Teva Pharmaceuticals USA Inc. (Teva Pharmaceutical Industries Ltd.).

Report Scope:

Report Features Details
Base Year of the Analysis 2023
Historical Period 2018-2023
Forecast Period 2024-2032
Units US$ Billion
Therapeutic Class Covered Anticonvulsants, Corticosteroids, Others
Drug Type Covered Vigabatrin, Adrenocorticotropic Hormone, Other(Phase III)
Dosage Covered Solid, Liquid
Route of Administration Covered Oral, Parenteral, and Others
Distribution Channel Covered Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
End User Covered Hospitals, Clinics, Others
Region Covered  Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered H. Lundbeck A/S, Mallinckrodt plc, ORPHELIA Pharma, Teva Pharmaceuticals USA Inc. (Teva Pharmaceutical Industries Ltd.), etc.
Customization Scope 10% Free Customization
Report Price and Purchase Option Single User License: US$ 3899
Five User License: US$ 4899
Corporate License: US$ 5899
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

134 N 4th St.
Brooklyn, NY 11249, USA
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Global Infantile Spasms Therapeutics Market to Reach US$ 5.1 Billion by 2032, Facilitated by Increasing Incidences of Infantile Spasms
Purchase options

Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Get in Touch With Us

Phone: +1-631-791-1145


Phone: +91-120-433-0800


Phone: +44-753-714-6104


Client Testimonials

Aktive Services

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

Read More
Greenfish S.A.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

Read More
Colruyt Group

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Read More

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

Read More
Zee Media Corp. Ltd.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Read More
Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

Read More
Sumitomo Corporation

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

Read More
Hameln Rds

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

Read More
Quality Consultants BV

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

Read More
TATA Advanced Systems Limited

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

Read More

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

Read More